Caron Center launches GLP-1 for addiction program supported by CASPR
Novel program will integrate GLP-1 receptor agonist (GLP-1RA) therapy into residential treatment programs for individuals in early recovery
CASPR is honored to support a new, groundbreaking program at Caron, that will provide GLP-1 therapy to substance use disorder patients. The Bridge Initiative at Caron Treatment Centers, led by Steven Klein M.D.,Ph.D. will add GLP-1RA therapy into residential treatment programs for individuals in early recovery.
From Caron’s announcement:
We’re proud to share news that Dr. Steven Klein M.D.,Ph.D., a leader in addiction medicine at Caron, received a pilot grant from the CASPR - Center for Addiction Science, Policy, and Research to launch The BRIDGE Initiative – Building Recovery with Innovative Delivery of GLP-1Ras for Expanded treatment!
This groundbreaking project aims to integrate GLP-1 receptor agonist (GLP-1RA) therapy into residential treatment programs for individuals in early recovery. GLP-1RAs, traditionally used for diabetes and weight management, have shown promise in reducing cravings associated with substance use disorders. A collaborative study between Caron and Penn State College of Medicine found that combining GLP-1RAs with traditional medication-assisted treatment significantly reduced opioid cravings compared to a placebo.
The BRIDGE Initiative seeks to expand access, strengthen outcomes and create a sustainable path for long term recovery beyond treatment. With CASPR’s support and Caron’s commitment to evidence-based care, we’re building a model with the potential to shape the future of residential addiction treatment nationwide."
And in Dr. Klein's words:
"We can no longer remain passive as barriers imposed by pharmaceutical companies and insurance providers obstruct access to effective treatment for substance use disorders. The growing body of evidence supporting the efficacy of GLP-1 receptor agonists in the treatment of addiction underscores the urgency of expanding access to these medications.
The Bridge Initiative is committed to promoting equitable access to these life-saving treatments and ensuring their timely delivery to the individuals who need them most. Caron has a distinguished history of integrating cutting-edge scientific innovation with evidence-based recovery principles to deliver truly comprehensive care.
With the generous support of CASPR, we are proud to carry this tradition forward—prioritizing patient recovery and advancing the frontiers of addiction treatment. This initiative would not be possible without CASPR’s unwavering support, and we commend their deep commitment to the continued advancement and refinement of addiction care."
You can also read Steve’s personal story of GLP-1s in his personal and professional life, which he published on Recursive Adaptation a few months ago. Steve is also a member of our GLP-1 for SUD prescribers’ email list, which you can learn about here— we now have dozens of doctors and researchers from major hospitals and research universities in that group.
Caron Treatment Centers is one of the well-regarded SUD organizations in the world, and has been supporting patients with substance use disorders for nearly 70 years, across facilities nationwide. Their focus on the whole person informs their treatment approach, which combines proven treatment and innovative approaches across the biological, psychological, and social aspects of addiction.
